Genzyme reports new survival data with clofarabine
Genzyme updated information for their CLASSIC II investigational study on Clolar (clofarabine). The estimated median overall survival data was 72 weeks for patients achieving complete remission, the company said.
Genzyme updated information for their CLASSIC II investigational study on Clolar (clofarabine). The estimated median overall survival data was 72 weeks for patients achieving complete remission, the company said. The estimated median survival for acute myeloid leukemia patients achieving overall remission was 59 weeks. The new estimated median duration of remission data and disease-free survival data suggest Clolar produced durable remissions in the patient population, according to the company.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
!["This [network meta-analysis] demonstrated for the first time that [anlotinib/benmelstobart plus chemotherapy] is the most efficacious regimen for extending survival in ES-SCLC, highlighting its potential as a preferred first-line treatment option for this patient population," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6934d676a539495d8b2109e4b3762700aa723bf3-1200x873.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"This [network meta-analysis] demonstrated for the first time that [anlotinib/benmelstobart plus chemotherapy] is the most efficacious regimen for extending survival in ES-SCLC, highlighting its potential as a preferred first-line treatment option for this patient population,\" according to the study authors.")
